Chief Barner To Pass Baton To Baumbach At Boehringer
This article was originally published in Scrip
Executive Summary
Professor Dr Andreas Barner is to step aside from the helm of family-owned Boehringer Ingelheim, to be succeeded by current finance chief, Hubertus von Baumbach, who is a member of the founding family. Barner will move from the role of chairman of the board of managing directors (effectively the CEO position) that he has held since 2009 to join the company's shareholders' committee, which is the equivalent of a supervisory board and is chaired by Christian Boehringer, another scion of the founder.
You may also be interested in...
20 Voices: What Does 2024 Hold For Biopharma?
20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 5: Clinical Trial Trends
Some 50 experts and executives in the biopharma sector shared their views on the major trends they expect to see driving change in the clinical trials arena in 2024. Artificial intelligence applied to clinical development, greater use of remote monitoring and increased patient diversity in trials were key themes.